New York Jets running back Chris Johnson underwent offseason knee surgery, which left some teams skeptical about his health moving forward and ultimately delayed his ability to sign with a new team.
Eventually, the Jets agreed to terms with Johnson, but now we know more about exactly what type of surgery the running back had during the offseason.
According to Sports Illustrated, Johnson had stem-cell treatment surgery.
“When I tore my meniscus and played the season out, through the wear and tear, I lost a lot of cartilage,” Johnson said. “When you put the stem cells in, it might be able to help rebuild that cartilage in your knee. Hopefully, it makes your knee better for even more years.”
How does the surgery work?
Here is a little explanation from the report:
On the day of his surgery at the Andrews Institute in Gulf Breeze, Fla., Johnson had a small amount of his bone marrow—60 milliliters, or the volume of a shot glass—siphoned out of the iliac crest of his pelvis with a long needle pushed through a tiny incision in his skin. Less than an hour later, at the end of the arthroscopic procedure to repair his meniscus, a concentrate of thousands of stem cells from the bone marrow was injected directly into Johnson’s knee joint.
Stem-cell treatment is gaining in popularity among athletes, so it will be interesting to see how it helps Johnson out.
The Jets are hoping that he can return to his old form and provide an explosive threat to their offensive backfield.
Could we see the return of CJ2k? We will begin to find out in a matter of weeks.